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http://dx.doi.org/10.1016/j.ccell.2015.07.002SUMMARYThe fibroblast growth factor (FGF)/FGF receptor (FGFR) system plays a crucial role in cancer by affecting
tumor growth, angiogenesis, drug resistance, and escape from anti-angiogenic anti-vascular endothelial
growth factor therapy. The soluble pattern recognition receptor long-pentraxin 3 (PTX3) acts as a multi-
FGF antagonist. Here we demonstrate that human PTX3 overexpression in transgenic mice driven by the
Tie2 promoter inhibits tumor growth, angiogenesis, and metastasis in heterotopic, orthotopic, and autoch-
thonous FGF-dependent tumor models. Using pharmacophore modeling of the interaction of a minimal
PTX3-derived FGF-binding pentapeptide with FGF2, we identified a small-molecule chemical (NSC12) that
acts as an extracellular FGF trap with significant implications in cancer therapy.INTRODUCTION
Fibroblast growth factors (FGFs) are heparin-binding polypep-
tides produced by stromal and parenchymal tumor cells and
are readily sequestered into the extracellular matrix by heparan
sulfate proteoglycans (HPSGs). FGFs bind tyrosine kinase
(TK) FGF receptors (FGFR1–FGFR4), leading to the formation
of signaling HSPG/FGF/FGFR ternary complexes (Beenken
and Mohammadi, 2009). Activation of the FGF/FGFR system
by overexpression, oncogenic mutations, or gene amplifications
is implicated in key steps of tumor growth and progression
(Beenken and Mohammadi, 2009). Moreover, compensatory
upregulation of the FGF/FGFR system may facilitate the escapeSignificance
The FGF/FGFR system is an attractive target for cancer therap
sine kinase or extracellular domains of FGFRs have been deve
sion of human PTX3 in transgenic mice inhibits tumor growth a
FGF-dependent tumormodels. These observations set the bas
derived small molecule, NSC12, acting as an extracellular FG
activation, tumor growth, angiogenesis, and metastasis in FG
resents a small-molecule ligand trap that can be developed wfrom angiostatic anti-vascular endothelial growth factor (VEGF)
blockade (Casanovas et al., 2005; Lieu et al., 2011). Thus, exper-
imental and clinical evidence provides a compelling biologic
rationale for the development of anti-FGF/FGFR targeting agents
in cancer therapy.
Thus far two major classes of FGFR inhibitors have been
developed: small-molecule intracellular TK inhibitors and extra-
cellular anti-FGFR antibodies or peptides (Ho et al., 2014). How-
ever, FGFR redundancy, limited selectivity, and significant
toxicity of TK inhibitors and proteinaceous origin of extracellular
FGFR antagonists may represent significant challenges for the
development of effective anti-cancer drugs. An alternative or
complementary approach may derive from the observation thaty. To date, only small-molecule inhibitors targeting the tyro-
loped. Here we show that Tie2 promoter-driven overexpres-
ndmetastasis in heterotopic, orthotopic, and autochthonous
is for pharmacophore modeling and identification of a PTX3-
F trap. Parenteral and oral delivery of NSC12 inhibits FGFR
F-dependent murine and human tumor models. NSC12 rep-
ith therapeutic significance in cancer therapy.
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FGFs are highly expressed in certain human tumors and exert
paracrine and autocrine functions on cancer epithelial and
stromal cells (Brooks et al., 2012), thus providing druggable
targets for the development of ‘‘two-compartment’’ anti-FGF
agents (Dieci et al., 2013), as hypothesized for soluble ‘‘decoy’’
FGFRs (Harding et al., 2013; Ho et al., 2014), heparin derivatives,
and polysulphated or polysulphonated compounds (Presta
et al., 2005). However, the possibility of developing small
organic molecules as extracellular multi-FGF ligand traps re-
mains underexplored.
The soluble pattern recognition receptor long pentraxin-3
(PTX3) is produced by endothelial and immune cells in response
to inflammatory signals (Garlanda et al., 2005). PTX3 binds
various FGFs via its N-terminal extension, including FGF2,
FGF6, FGF8b, FGF10, and FGF17, and inhibits FGF-dependent
angiogenic responses (Camozzi et al., 2006; Leali et al., 2011;
Presta et al., 2007; Ronca et al., 2013a). Accordingly, the acety-
lated pentapeptide Ac-ARPCA-NH2 (in single-letter code, here-
after referred to as ARPCA), corresponding to the N-terminal
amino acid sequence PTX3(100–104), acts as a minimal anti-
angiogenic FGF-binding peptide able to interfere with FGF/
FGFR interaction (Leali et al., 2010). Thus, PTX3 represents
a natural multi-FGF trap with potential implications for tumor
therapy. Indeed, PTX3-overexpressing FGF-dependent tumor
cells show a reduced angiogenic and tumorigenic potential
(Leali et al., 2011; Ronca et al., 2013a, 2013b).
Here, the effect of endothelial human PTX3 (hPTX3) overex-
pression on FGF-dependent tumor progression was evaluated
in transgenic mice, and pharmacophore modeling was used to
identify a PTX3-derived small molecule acting as a FGF trap in
cancer therapy.
RESULTS
Generation of Transgenic hPTX3-Expressing
TgN(Tie2-hPTX3) Mice
To mimic the effect of a local and systemic delivery of hPTX3
on tumor growth, we generated transgenic TgN(Tie2-hPTX3)
mice expressing hPTX3 under the control of the endothelial-
specific Tie2/Tek transcription regulatory sequences. hPTX3 is
expressed in various organs of these mice where it accumulates
in the perivascular and stromal microenvironment (Figures 1A
and 1B), leading to a significant increase of hPTX3 serum levels
(105 ± 20 ng/ml versus < 1.8 ng/ml in transgenic and wild-type
animals, respectively).
As anticipated, lung endothelial cells isolated from TgN(Tie2-
hPTX3) animals showed impaired FGFR1 activation following
stimulation by FGF2 when compared to wild-type cells (Fig-
ure 1C). In addition, aorta rings harvested from TgN(Tie2-
hPTX3) mice and embedded in fibrin gel in the presence of
FGF2 showed a reduced capacity to form endothelial cell
sprouts but retained a full response to VEGF-A (Figure 1D).
Finally, the angiogenic activity of FGF2 was significantly reduced
in a subcutaneous (s.c.) Matrigel plug assay performed in
TgN(Tie2-hPTX3) animals (Figure 1E). Notably, constitutive
hPTX3 expression does not result in apparent defects in embry-
onic and post-natal development and in body weight gain; adult
animals are fertile with no histological alterations of all tissues
examined, including heart, liver, lungs, and kidney (data not226 Cancer Cell 28, 225–239, August 10, 2015 ª2015 Elsevier Inc.shown). Moreover, no significant changes in the expression
levels of PTX3-targeted FGFs, including Fgf2, Fgf6, Fgf8,
Fgf10, and Fgf17 (Ronca et al., 2013a), was observed in different
organs of TgN(Tie2-hPTX3) mice when compared to wild-type
animals (Figure S1).
Tie2 Promoter-Driven Expression of hPTX3 Impairs
Heterotopic Tumor Growth and Neovascularization
Transgenic adenocarcinoma of themouse prostate (TRAMP)-C2
cells are a prototypic prostate carcinoma model driven by auto-
crine, androgen-upregulated FGF2 and FGF8b (Ronca et al.,
2013a). To assess the impact of hPTX3 overexpression on the
early phases of FGF-dependent tumor growth, we performed a
short-term experiment in which TRAMP-C2 cells embedded in
alginate plugs were injected s.c. in male TgN(Tie2-hPTX3)
mice. After 2 weeks, alginate pellets grafted in transgenic ani-
mals showed a significant reduction of FGFR1 phosphorylation
when compared to plugs implanted in wild-type animals,
providing experimental evidence of the capacity of transgenic
hPTX3 overexpression to disrupt ligand-dependent FGFR acti-
vation in vivo (Figures 2A and 2B). Accordingly, tumor cell prolif-
eration rate and vascularization were drastically impaired in
TRAMP-C2 plugs grafted in TgN(Tie2-hPTX3) mice (Figure 2C)
with a significant inhibition of TRAMP-C2 tumor growth in a
long-term s.c. assay (Figure 2D).
A significant reduction of tumor growth was observed in
TgN(Tie2-hPTX3) mice also after s.c. injection of FGF-dependent
B16-F10 melanoma cells or Lewis lung carcinoma (LLC) cells, a
model in which the FGF/FGFR axis is associated with tumor
growth and resistance to anti-VEGF therapy (Figure 2D) (Shojaei
et al., 2009). Notably, no difference in the rate of tumor growth
occurred in TgN(Tie2-hPTX3) animals graftedwith FGF-indepen-
dent TC-1 or C3 cancer cells (Figure S2A) (Accardi et al., 2014).
Similarly, hPTX3 overexpression did not affect the growth of
FGFR1-TRAMP-C2 lesions transduced with a constitutively
activated form of the intracellular FGFR1 TK domain (Hart
et al., 2000) and characterized by a faster rate of growth when
compared to parental TRAMP-C2 tumors (Figure S2B).
hPTX3 overexpression inhibited the growth, proliferation rate,
and vascularization of experimental liver metastases after intra-
venous (i.v.) injection of M5076 reticulum cell sarcoma cells (Fig-
ures 2E and 2F) (Talmadge and Hart, 1984). A similar inhibition
was observed for the growth of B16-F10 melanoma lung metas-
tases (Figures 2G and 2H) that occurred in the absence of any
effect of hPTX3 expression on B16-F10 cell homing to the lungs
(Figure S2C). In contrast, no difference in lung colonization
was observed between wild-type and TgN(Tie2-hPTX3) animals
following i.v. injection of FGF-independent TC-1 cells (Fig-
ure S2D). Together, these data support the notion that the anti-
tumor effect of hPTX3 is related to its extracellular inhibitory
action on the autocrine and paracrine loops of stimulation trig-
gered by the FGF/FGFR system in FGF-dependent tumors.
Tie2-expressing monocytes (TEMs), a bone marrow (BM)-
derived cell population homing the tumor microenvironment,
may act as cell shuttles for a tumor-targeted delivery of anti-
cancer therapeutics (De Palma et al., 2007). On this basis,
we generated chimeric mice by myelodepletion of wild-type
animals followed by reconstitution with the BM harvested
from TgN(Tie2-hPTX3) or control GFP-expressing transgenic
Figure 1. Transgenic TgN(Tie2-hPTX3) Mice
(A) RT-PCR and western blot analyses of the expression of transgenic hPTX3 in wild-type (WT) and TgN(Tie2-hPTX3) mice.
(B) Immunostaining of CD31 (blood vessels) and hPTX3 protein.
(C) Immunostaining for pFGFR1 and CD31 of FGF2-stimulated endothelial cells isolated from WT and TgN(Tie2-hPTX3) lungs. Intensity of pFGFR1 signal was
quantified and normalized to DAPI area. The boxes extend from the 25th to the 75th percentiles, lines indicate the median values, and whiskers indicate the range
of values. Inset: RT-PCR analysis on isolated cells.
(D) Quantification of the number of sprouts at day 6 and representative images of fibrin-embedded aorta rings from WT and TgN(Tie2-hPTX3) mice treated with
FGF2 or VEGF-A.
(E) qRT-PCR (n = 8 mice/group) and immunofluorescence analyses of CD31 expression in vehicle and FGF2 Matrigel plugs.
Scale bars, 50 mm (B and E), 30 mm (C), and 400 mm (D). Data are mean ± SEM. *p < 0.05, and #p < 0.001. See also Figure S1.TgN(Tie2-GFP) mice (Figures S2E and S2F). As shown in
Figure 2I, myeloid-cell-mediated delivery of hPTX3 by TEMs
infiltrating the s.c. TRAMP-C2 tumors (Figure S2G) caused a
significant delay of tumor growth in chimeric TgN(Tie2-hPTX3)
BM-transplanted mice when compared with tumors grafted in
TgN(Tie2-GFP) BM-transplanted animals. The inhibitory effect
was paralleled by a significant reduction of tumor cell prolifera-
tion, but not of tumor vascularization (Figures S2H and S2I),
possibly as a consequence of the lower local and systemic con-centration of hPTX3 produced by transplanted myeloid cells
compared to hPTX3 transgenic animals.
Tie2 Promoter-Driven hPTX3 Production Impairs
Orthotopic and Autochthonous Multistage
Tumor Growth
Next, we evaluated the effect of stroma-derived hPTX3 on
the growth of syngeneic murine pancreatic and mammary carci-
noma cells orthotopically grafted in TgN(Tie2-hPTX3) mice.Cancer Cell 28, 225–239, August 10, 2015 ª2015 Elsevier Inc. 227
(legend on next page)
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When compared to wild-type animals, intra-pancreatic injection
of Panc02 tumor cells in TgN(Tie2-hPTX3) mice resulted in a sig-
nificant reduction of tumor burden and enhancement of animal
survival (Figure 3A). Similarly, a significant delay in the appear-
ance of mammary tumor nodules, decreased tumor growth,
and increased survival time were observed in female TgN(Tie2-
hPTX3) mice with respect to control animals after transplantation
of syngeneic EO771 breast carcinoma cells into the mammary
fat pad (Figure 3B).
TRAMPmice represent an autochthonousmultistagemodel of
prostate cancer in which the FGF/FGFR system plays a relevant
role (Polnaszek et al., 2003). To further assess the anti-neoplastic
potential of the FGF trap activity of hPTX3, the prostatic tumor
progression in double-transgenic TgN(Tie2-hPTX3)/TRAMP
mice was compared to the progression in age-matched TRAMP
animals at 10 and 12 weeks of age. Quantitative histological
analysis revealed a lower incidence of well-differentiated and
moderately differentiated tumors (Figure 3C) and a reduction
of Ki67+ tumor cells (Figure 3D) in TgN(Tie2-hPTX3)/TRAMP
mice, index of significant delay of prostatic tumor progression
in hPTX3-expressing mice. This effect was transient and was
not observed at later stages of tumor progression in which
poorly differentiated or neuroendocrine tumors arose (data
not shown), possibly due to compensatory mechanisms that
overcome FGF inhibition by PTX3. Even though further experi-
ments will be required to assess the mechanisms able to
overcome PTX3-mediated oncosuppressive effects, the data
clearly show that PTX3 can delay, at least transiently, the pro-
gression of prostate cancer in the TRAMP model.
Homozygous Ptx3 Inactivation Enhances
FGF-Dependent Angiogenesis, Tumor Growth,
and Metastasis
Ptx3/ mice develop normally and do not show any gross
abnormality, even though Ptx3/ females are subfertile. PTX3
deficiency causes a reduced immune response to pathogens
and increases tissue damage in ischemic myocardium and
atherosclerotic lesions (seeDaigo et al. [2014] for amore detailed
description of the Ptx3/ mouse phenotype). Also, recent
observations have shown that the growth of chemical carcin-
ogen-induced skin tumors is delayed in these animals (Bonavita
et al., 2015). To further evaluate the impact of PTX3 on tumor
growth, we compared the angiogenic activity of FGF2 protein
and the tumorigenic and metastatic activity of melanoma
B16-F10 cells when assessed in syngeneic Ptx3/mice versus
wild-type and TgN(Tie2-hPTX3) animals. As shown in Figure 3E,Figure 2. Transgenic hPTX3 Expression Impairs Heterotopic Tumor G
(A) FGFR1 and pFGFR1 immunostaining and pFGFR1/FGFR quantification norm
(B) Western blot analysis and pFGFR1/FGFR1 quantification normalized to b-act
(C) PTX3, CD31, and Ki67 immunostaining, CD31+ and Ki67+ quantification norma
normalized to 18S rRNA. Eight to ten mice/group in (A)–(C).
(D) Growth of s.c. TRAMP-C2, LLC, and B16-F10 tumors in WT and TgN(Tie2-hP
(E–H) M5076 (E and F) and B16-F10 (G and H) cells were injected i.v. in WT and T
were weighed, and macroscopic metastases were counted. Liver (F) and lungs
stained for Ki67.
(I) Growth of s.c. TRAMP-C2 tumors in WT chimeric mice reconstituted with TgN
Scale bars, 30 mm (A), 100 mm (F [CD31/PTX3 and Ki67], H [Ki67]), 200 mm (H
and whiskers graphs, boxes extend from the 25th to the 75th percentiles, lines ind
**p < 0.01, and #p < 0.001. See also Figure S2.Ptx3 knockout results in a significant increase of both basal
and FGF2-triggered angiogenic responses in the Matrigel plug
assay when compared to those observed in TgN(Tie2-hPTX3)
and wild-type animals. It must be pointed out that the s.c. injec-
tion of Matrigel induces per se a mild pro-inflammatory reaction,
leading to the co-expression within the plug of PTX3 and FGF2,
thus explaining the effect of Ptx3 knockout on the basal neovas-
cular response in this assay (Leali et al., 2012). In agreement with
these observations, the tumorigenic and metastatic activities of
B16-F10 cells were significantly enhanced in Ptx3 null animals in
respect to wild-type and hPTX3-overexpressing mice (Figures
3F and 3G). Thus, PTX3 appears to act as a natural brake of
FGF-mediated angiogenesis, tumor growth, and metastasis.
This inhibitory activity is further enhanced by Tie2 promoter-
driven hPTX3 overexpression in tumor-bearing mice. These
observations paved the way for the exploitation of the FGF
trap activity of PTX3 in cancer therapy and for the development
of PTX3-derived anti-FGF synthetic compounds.
Identification of a PTX3-Derived Small-Molecule
FGF Trap
PTX3 is a 340-kDa protein composed of eight protomers of 381
amino acids each (Inforzato et al., 2010). The complex proteina-
ceous structure of PTX3 hampers its pharmacological exploita-
tion. In this context, we identified the acetylated pentapeptide
PTX3(100–104) ARPCA as the minimal amino acid sequence
able to bind FGF2 and interfere with FGF2/PTX3 and HSPG/
FGF2/FGFR1 interactions (Leali et al., 2010). ARPCA acts as a
potent FGF2 and FGF8b antagonist (Leali et al., 2010; Ronca
et al., 2013a; Giacomini et al., 2015), representing a useful start-
ing point for the rational identification of low-molecular-weight,
nonpeptidic FGF antagonists.
On this basis, an atomistic model of the ARPCA/FGF2 com-
plex was generated to identify the physico-chemical determi-
nants required for productive ARPCA/FGF2 interaction. This
information was translated into a pharmacophore model for the
identification of drug-like hits via the screening of small-molecule
libraries (Colombo et al., 2010). First, the principal conformations
populated by ARPCA in solution, derived from a 200-ns-long
explicit water molecular dynamics (MD) simulation, were sub-
jected to multiple docking runs on the FGF2 surface, followed
byMD refinement of the resulting complex (100 ns). The results
(detailed in the Supplemental Information) showed that ARPCA
engages the FGF2 surface that faces the D2-D3 linker and D3
domain of FGFR (Plotnikov et al., 1999). The analysis of the sta-
tistical distribution of ARPCA/FGF2 interactions was consistentrowth
alized to DAPI area.
in.
lized to DAPI area, and relative levels of CD31 and cyclin D1 mRNA expression
TX3) mice (n = 10–12 mice/group).
gN(Tie2-hPTX3) mice (n = 10 mice/group). After 3 weeks, liver (E) and lungs (G)
(H) were H&E stained, double-immunostained for CD31/PTX3, and immuno-
(Tie2-hPTX3) or control TgN(Tie2-GFP) bone marrow (BM); n = 10 mice/group.
[CD31/PTX3]), and 400 mm (F and H [H&E]). Data are mean ± SEM. In box
icate the median values, and whiskers indicate the range of values. *p < 0.05,
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Figure 3. Transgenic hPTX3 Expression
Impairs Orthotopic and Multistage Tumor
Growth
(A) Imaging of Panc02-luc prostate cancer cells 9
and 20 days after orthotopic injection in WT and
TgN(Tie2-hPTX3) mice (top panel) and Kaplan-
Meyer survival curves (n = 8–10 mice/group)
(bottom panel).
(B) Tumor growth, harvested tumors (top panel),
and Kaplan-Meyer survival curves (bottom panel)
for EO771 mammary carcinoma grafts (n = 10
mice/group).
(C) Histopathological analysis of anterior prostate
lobes from 10- and 12-weeks-old TRAMP and
TRAMP/Tie2-hPTX3 mice (n = 8–12 mice/group).
Left graph shows the percentage of pathologic
area on total prostatic area; right graph shows
the percentage of pathologic glands with well-
differentiated (WD) carcinoma areas. Each dot
represents a single tissue field, and lines indicate
the median values.
(D) Representative images of anterior prostate
sections. Scale bar, 100 mm.
(E–G) qRT-PCR analysis of CD31 expression in
PBS and FGF2 Matrigel plugs (E), growth of s.c.
B16-F10 tumors (n = 10 mice/group) (F), and
quantification of B16-F10 end-stage lung meta-
static foci (G) in Ptx3/, WT, and Tie2-hPTX3
mice.
Data are mean ± SEM. The boxes extend from
the 25th to the 75th percentiles, lines indicate the
median values, and whiskers indicate the range
of values. *p < 0.05, **p < 0.01, #p < 0.001, and
ns = not significant.with previously published nuclear magnetic resonance (NMR)
saturation-transfer difference (STD) data, indicating that the pep-
tide contacts FGF2 via the methyl groups of Ala1 and Ala5 and
of the acetyl capping group (Leali et al., 2010). Next, the ARPCA
key functional groups, combined with the characterization of
their relative space orientations, were used to build a pharmaco-
phore model for the screening of the NCI2003 small-molecule
database containing 3 3 105 compounds (Developmental
Therapeutics Program NCI/NIH at https://dtp.cancer.gov/).
Filtering of the resulting set according to the Lipinsky
drug-likeness rules returned 25 compounds. Ten of them,
made available from the National Cancer Institute (NCI), were
subjected to a preliminary screening for their capacity to
prevent the formation of HSPG/FGF2/FGFR1(IIIc) ternary
complexes in a FGF2-mediated cell-cell adhesion assay. This230 Cancer Cell 28, 225–239, August 10, 2015 ª2015 Elsevier Inc.assay is based on the capacity of
FGFs to interact simultaneously in trans
with HSPGs and FGFRs expressed on
neighboring cells, thus causing FGF-
mediated cell-cell adhesion (Richard
et al., 1995); FGF antagonists hamper
FGF-mediated intercellular adhesion by
binding FGF and preventing its interac-
tion with HSPGs or FGFRs (Leali et al.,
2010). As shown in Figure S3A, the
480-Da compound 4,4,4-trifluoro-1-(3-hydroxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodeca-
hydro-1H-cyclopenta[a]phenanthren-17-yl)-3-(trifluoromethyl)
butane-1,3-diol (NSC172285, herewith named NSC12; Fig-
ure 4A) prevented the formation of the HSPG/FGF2/FGFR1
complex (half maximal inhibitory concentration (IC50) 10 mM;
Figure 4B), whereas the other compounds were devoid of
significant activity. On this basis, NSC12 was characterized
further, and the NSC21 compound was used as a negative
control.
In a first set of experiments, NSC12 was investigated by
surface plasmon resonance (SPR) analysis for its capacity to
prevent the binding of FGF2 to heparin immobilized to a BIAcore
sensor chip or to an immobilized sFGFR1(IIIc)/Fc chimera.
As shown in Figure 4C, NSC12 does not affect FGF2/heparin
interaction, whereas it inhibits the binding of FGF2 to the
Figure 4. NSC12 as a Small-Molecule PTX3-
Derived FGF Trap
(A) Schematic representation of multimeric PTX3
protein, highlighting the N-terminal FGF-binding
region ARPCA, and chemical structure of NSC12.
(B) Inhibition of HSPG/FGF2/FGFR1 ternary com-
plex formation by NSC12.
(C) SPR competition assay for FGF2 binding to
FGFR1 and heparin sensor chips in the presence
of 100 mM NSC12 or NSC21.
(D) SPR and CONAMORE analysis of NSC12 af-
finity and binding on FGF2 sensor chip.
(E) Representation of the main binding mode of
NSC12 predicted by docking and MD simulation
of NSC12/FGF2 complex. NSC12 and the FGF2
side chains in contact with NSC12 are shown
as blue and cyan sticks, respectively, whereas
FGF2 and FGFR (PDB ID 1fq9) are shown as
yellow and gray cartoons, respectively. Magenta
spheres refer to FGF2 residues involved in ARPCA
interactions as deduced by MD simulations.
(F) Affinity (Kd) of NSC12/FGF interactions
assessed by SPR.
(G and H) NSC12 inhibits HSPG/FGF/FGFR1
ternary complex formation by FGFR1(IIIc)-binding
FGFs (G) and MMT-assessed KATO III cell prolif-
eration triggered by FGFR2(IIIb)-binding FGFs (H).
Data are mean ± SEM. NS, not stimulated.
*p < 0.05, **p < 0.01, and #p < 0.001. See also
Figure S3.immobilized receptor (ID50 30 mM). No effect was exerted by
NSC21 on either sensor chip. Thus, as observed for PTX3/
FGF2 and ARPCA/FGF2 complexes (Leali et al., 2010), NSC12
interferes with FGF2/FGFR1 interaction without affecting the
ability of the growth factor to interact with heparin or HSPGs.
The capacity of NSC12 to bind to immobilized FGF2 was
confirmed by SPR spectroscopy. The SPR binding isotherm
(Figure 4D) shows a Langmuir-like shape for monovalent
binding with a dissociation constant (Kd) equal to 51 ± 7 mM.
The 1:1 stoichiometry of the FGF2:NSC12 interaction was
confirmed also by surface density SPR measurements (Maiolo
et al., 2012) performed at 100 mM NSC12 and showing thatCancer Cell 28, 225–2391.28 3 1010 molecules/mm2 of NSC12
bind to 1.453 1010molecules/mm2 of im-
mobilized FGF2.
FGF2/NSC12 interaction was investi-
gated also by the contact anglemolecular
recognition (CONAMORE) biosensor
that probes the nanomechanical aspects
of binding, complementing the informa-
tion obtained by SPR (Maiolo et al.,
2012). The CONAMORE binding isotherm
performed on the same FGF2 chip
used for SPR (Figure 4D) evidences that
the onset of significant nanomechanical
effects of FGF2 binding occurs at
40 mM NSC12, consistent with the Kd
calculated by SPR. In addition, no nano-
mechanical effect is registered when
NSC12 is run onto a urea-denaturedFGF2 chip (Figure 4D), further pointing to the specificity of the
interaction.
Docking and MD simulations performed on the NSC12/FGF2
system indicated that NSC12 and ARPCA, while sharing the
same pharmacophoric points necessary to anchor FGF2, do
not target entirely identical or overlapping regions on the FGF2
molecule, as expected given their different chemical nature
and pharmacophore design. Indeed, besides engaging the
FGF2 surface that faces the D2-D3 linker and D3 domain of
FGFR, NSC12 further extends into the FGF2 region facing the
FGFR D2 domain (D2), as detailed in the Supplemental Informa-
tion and in Figure 4E. On this basis and given that the D3 domain, August 10, 2015 ª2015 Elsevier Inc. 231
does not adopt a stable persistent three-dimensional fold in
solution (Herbert et al., 2013), the D2 domain was used as a
probe to investigate the overall effects of NSC12 on the FGF2/
FGFR complex by NMR. Relaxation data demonstrate that
NSC12 shifts the FGF2/D2 equilibrium toward the uncomplexed
forms, as deduced from the decrease of the average 15N trans-
verse relaxation rate value measured for D2 and FGF2 upon
NSC12 addition to the D2/FGF2 complex (Supplemental Infor-
mation and Figure S3B).
Finally, when tested by SPR analysis on all canonical FGFs
(Itoh and Ornitz, 2004), NSC12 also binds immobilized FGF3,
FGF4, FGF6, FGF8, FGF16, FGF18, FGF20, and FGF22 with
Kd values ranging between 16 and 120 mM (Figure 4F). No
apparent interaction was observed for the other FGFs tested,
possibly because of the limited sensitivity of the method due to
the low molecular weight of NSC12 or to the low efficiency
of the immobilization procedure for some of the FGFs tested.
On this basis, the capacity of NSC12 to affect the activity of
FGFR1(IIIc)-binding FGFs and of FGFR2(IIIb)-binding FGFs
(Zhang et al., 2006) was assessed by the HSPG/FGF/FGFR1
ternary complex assay described above and by a KATO III cell
proliferation methylthiazol tetrazolium (MTT) assay (Bai et al.,
2010), respectively. As shown in Figures 4G and 4H, NSC12
inhibits HSPG/FGF/FGFR ternary complex formation induced
by FGFR1(IIIc)-binding FGF1, FGF4, FGF5, FGF6, FGF8, FGF9,
FGF16, FGF17, FGF18, and FGF20 and the proliferative capacity
of FGFR2(IIIb)-binding FGF3, FGF7, FGF10, and FGF22 in KATO
III cells. Together with its FGF2 antagonist activity, these data
indicate that NSC12 may act as a multi-FGF trap by interacting
with all members of the canonical FGF subfamilies. In addition,
when assessed for its ability to interact with hormonal FGFs,
SPR analysis showed the capacity of NSC12 to bind FGF21
(Kd = 53 ± 13 mM) but failed to detect a significant interaction
with immobilized FGF19 or FGF23. However, when tested on
MDA-MB-361 breast cancer cells, the compound was able to
inhibit ERK1/2 phosphorylation and the mitogenic response
elicited by all hormonal FGFs in these cells (Figure S3C). Accord-
ingly, NSC12 hampered FGF23-mediated FGFR1 activation
in Klotho-expressing Chinese hamster ovary (CHO) cells (Fig-
ure S3D) (Urakawa et al., 2006).
NSC12 Inhibits FGF-Dependent Angiogenesis
and Tumor Cell Proliferation
In keeping with its capacity to antagonize FGF2/FGFR1 interac-
tion, NSC12 inhibited FGFR1 phosphorylation in human umbili-
cal vein endothelial cells (HUVECs) stimulated by FGF2 with a
significant inhibition of HUVEC proliferation (IC50 6.5 mM)
mainly due to their accumulation in the G0/G1 phase of the cell
cycle (Figures 5A and 5B). Also, NSC12 inhibited the sprouting
activity exerted by FGF2 on HUVEC spheroids embedded in
fibrin gel (Figure 5C) and impaired the angiogenic response trig-
gered by FGF2 in the chick embryo chorioallantoic membrane
(CAM) assay (Figure 5D). NSC12 had no effect on the activity
of VEGF-A in all these assays, and control NSC21 was inactive.
Thus, NSC12 acts as a selective anti-angiogenic FGF antago-
nist. Accordingly, the inhibitory activity exerted by NSC12
on endothelial cell proliferation, as well as on tumor cell prolifer-
ation (see below), was reversed by a molar excess of FGF2
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the FGF-mediated proliferation of murine (TRAMP-C2) and hu-
man (LNCaP and DU145) prostate cancer cells where FGFR1
is a driver of tumor growth and drug resistance (Figure 5E).
Similar results were obtained for FGF-dependent murine (LLC)
and human (H520) lung cancer cells characterized by FGFR1
overexpression or amplification, respectively (Figure 5F). As
observed for HUVECs, treatment with NSC12 caused the
reduction of the S phase of the cell cycle in all tumor cell lines
but LLC cells, in which an accumulation in the S phase was
observed (Figures 5E and 5F). Control NSC21 was inactive in
all the cell lines tested, and no inhibitory effect was observed
when FGF/FGFR-independent HCC827 lung cancer cells
(harboring a tumor-driving mutation of the epidermal growth
factor receptor [EGFR] TK domain) were challenged with
NSC12 (Figure 5F).
The inhibitory activity of NSC12 was not restricted to FGFR1-
dependent tumor cells. Indeed, the compound also affected the
proliferation of FGFR2-dependent KATO III gastric carcinoma
cells, FGFR3-dependent KMS-11 myeloma cells, and FGFR4-
dependent MDA-MB-361 breast cancer cells (Figure S4B).
Accordingly, NSC12 inhibited FGFR1, FGFR2, FGFR3, and
FGFR4 phosphorylation in CHO cell transfectants (Figure S4C).
To define a therapeutically effective dose and to assess the
FGF antagonist activity of NSC12 in vivo, TRAMP-C2 cells
were embedded in alginate plugs and grafted s.c. in syngeneic
male mice that were treated intraperitoneally (i.p.) every other
day for 1 week with increasing doses of NSC12 (from 2.5 to
10 mg/kg). NSC12 caused a significant decrease of tumor
weight, tumor cell FGFR1 phosphorylation and proliferation,
and tumor CD31+ neovascularization at all the doses tested,
whereas NSC21 was ineffective (Figures 6A–6C and S5A). Since
the 10-mg/kg dose resulted in a partial body weight loss
(Figure S5B), the 7.5-mg/kg dose was chosen for further
experimentation. This dose was sufficient to fully inhibit FGFR1
phosphorylation in TRAMP-C2/alginate implants (Figure 6D)
with no effect in 2-week-treated animals on body weight
(Figure S5B), hematologic parameters, and blood serum com-
ponents (Figure S5C). Remarkably, NSC12 treatment did
not affect serum concentration of endocrine FGFs, including
FGF23 (Figure S5D).
On this basis, additional short-term assays were performed on
FGF-dependent human cancer cells. To this aim, alginate plugs
containing human prostate cancer (DU145) or lung cancer
(H520) cells were injected s.c. in immunodeficient mice that
were treated i.p. every other day with 7.5 mg/kg NSC12 or
NSC21 for 1 week. As shown in Figures 6E and 6F, NSC12
caused a significant reduction of tumor weight and tumor
CD31+ neovascularization with a consequent increase of tumor
cell death (as assessed by TUNEL staining). Notably, in keeping
with in vitro observations, i.p. administration of NSC12 did not
exert any effect in vivo on FGF-independent HCC827 tumor
cells, causing only a limited inhibition of the scarce neovascular
response elicited by these cells (Figure 6G). Again, NSC21 was
ineffective in all the alginate plugs tested.
Together, these data provide strong experimental evidence
about the capacity of a small-molecule FGF trap to disrupt
FGF/FGFR signaling in vivo, leading to inhibition of tumor cell
proliferation and neovascularization in FGF-dependent tumors.
Figure 5. In Vitro Anti-tumor Effects of NSC12
(A and B) FGFR1 and pFGFR1 immunostaining (A), viable cell counting, and cell cycle analysis (B) of HUVE cells treated with FGF2, VEGF-A, or FBS in the
presence of NSC12 or NSC21.
(C) HUVE cell spheroids were stimulated with FGF2 or VEGF-A in the absence or presence of 1.0 mM NSC12 or NSC21. After 24 hr, the number of sprouts or
spheroids were counted.
(D) FGF2 and VEGF-A alginate pellets were placed on top of the chick embryo CAM at day 11 in the absence or presence of NSC12 or NSC21. At day 14 blood
vessels around the sponges were counted (n = 8 eggs/group).
(E and F) Viable cell counting and cell cycle analysis of prostate cancer cells (E) and lung cancer cells (F).
*p < 0.05, and #p < 0.001. Scale bars, 20 mm (A) and 100 mm (C). Data are mean ± SEM. For cell cycle analyses: p < 0.01, *S phase, G0/G1 phase, and
xG2/M
phase. See also Figure S4.
Cancer Cell 28, 225–239, August 10, 2015 ª2015 Elsevier Inc. 233
Figure 6. NSC12 Inhibits the FGF/FGFR System in FGF-Dependent Tumors
(A–D) Male mice were implanted s.c. with TRAMP-C2/alginate plugs and treated i.p. every other day with NSC12, NSC21, or vehicle (n = 4–6 mice/group). After
1 week, harvested plugs were weighed (A), processed for immunofluorescence analysis of FGFR1 and pFGFR1 (B) or of CD31and Ki67 (C) or for pFGFR1/FGFR1
quantification by western blot analysis of FGFR1 and pFGFR1 (data are normalized to b-actin; D).
(legend continued on next page)
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Inhibition of Tumor Growth by Parenteral and Oral
Delivery of NSC12
On the basis of results described above, NSC12 was assessed
for its capacity to inhibit the tumorigenic activity of FGF-depen-
dent TRAMP-C2 cells and of human prostate DU145 and lung
H520 tumor cells following i.p. administration in syngeneic and
nude mice, respectively. To this purpose, tumor cells were in-
jected s.c., and animals were randomly distributed in vehicle-,
NSC12-, or NSC21-treated groups when tumors were palpable.
As shown in Figure 7A, NSC12 exerted a significant inhibitory
effect on the growth of both murine and human tumor grafts,
whereas NSC21 was ineffective. Moreover, NSC12 inhibited
the formation of experimental lung metastases after i.v. injection
of B16-F10-luc cells (Figure 7B) and of spontaneous lungmetas-
tases induced by orthotopic grafting of breast carcinoma EO771
cells into the mammary fat pad followed by surgical removal of
the primary tumor (Figure 7C). In contrast, NSC12 did not affect
the growth of FGF-independent TC-1 and C3 tumor grafts or of
TRAMP-C2 and LLC lesions overexpressing the constitutively
activated form of the intracellular FGFR1 TK domain, thus con-
firming the specificity of the effect (Figure S6).
Finally, to establish whether NSC12 may also exert a signifi-
cant anti-tumor activity after oral administration, male mice
were injected s.c. with TRAMP-C2 cells embedded in alginate
plugs and treated by gavage with 7.5 mg/kg NSC12 or NSC21
for 4 days. Strikingly, gavage administration of NSC12 signifi-
cantly impaired FGFR1 phosphorylation in TRAMP-C2 plugs
when compared to plugs from animals treated with NSC21 or
vehicle (Figure 7D). To confirm the oral activity of NSC12 also
in human tumors, FGF-dependent H520 cells were grafted
s.c. in nude mice. When tumors were palpable, animals were
randomly distributed in three experimental groups and treated
orally with 7.5 mg/kg NSC12 or NSC21 or vehicle. As shown
in Figure 7E, gavage administration of NSC12 resulted in a sig-
nificant inhibition of H520 tumor growth that was confirmed by
measuring the end-stage tumor weight. This occurred in the
absence of any effect of drug administration on body weight
and survival of treated animals.
DISCUSSION
Here we demonstrate that Tie2 promoter-driven hPTX3 overex-
pression in transgenic mice inhibits tumor growth, angiogenesis,
and metastasis in heterotopic, orthotopic, and autochthonous
FGF-dependent tumor models. On this basis, pharmacophore
modeling of the interaction of the minimal PTX3-derived
FGF-binding pentapeptide ARPCA with FGF2 was used for the
identification of NSC12 as a small-molecule FGF trap active by
parenteral as well as by gavage administration in tumor-bearing
mice.
Several pieces of evidence support the hypothesis that the
oncosuppressive effects of hPTX3 are due to its capacity to(E–G) Mice implanted s.c. with alginate plugs containing FGF-dependent human
treated i.p. every other day with 7.5 mg/Kg NSC12, NSC21, or vehicle for 1 week (
analysis was performed.
Scale bars, 30 mm (B), 50 mm {E, F, and G [H&E]), and 100 mm (E, F, and G [CD31,
extend from the 25th to the 75th percentiles, lines indicate the median values, an
versus NSC12 at 2.5 and 5 mg/Kg. See also Figure S5.act as a natural FGF trap: (1) the endothelium of TgN(Tie2-
hPTX3) mice shows a reduced response to FGF2 in various
angiogenesis assays but retains a full capacity to respond to
VEGF stimulation; (2) inhibition of FGFR1 phosphorylation oc-
curs in FGF-dependent TRAMP-C2 cells grafted in TgN(Tie2-
hPTX3) mice; and (3) hPTX3 expression does not affect the
growth of FGF-independent TC-1 or C3 tumors. We cannot
rule out the possibility that PTX3 may have multiple impacts on
tumor growth (Bonavita et al., 2015). Nevertheless, our data sup-
port the notion that the anti-tumor effects of hPTX3 are related
to its inhibitory action on the autocrine and paracrine loops of
stimulation triggered by the FGF/FGFR system in FGF-depen-
dent tumors, setting the basis for the identification of a PTX3-
derived small-molecule FGF trap. Clearly different from FGFR
blockers, PTX3 and PTX3-derived FGF traps are anticipated to
be ineffective on tumors driven by ligand-independent FGFR
activation, as shown for FGFR1-TRAMP-C2 cells grafted in
TgN(Tie2-hPTX3) mice.
ARPCA, corresponding to the amino acid sequence PTX3
(100–104), represents the minimal FGF2-binding peptide able
to antagonize FGF2 activity by interacting with the FGFR-binding
region of the growth factor. These findings provided the bases
for the design of a pharmacophore model of ARPCA/FGF2 inter-
action that was used for in silico screening of the NCI2003 small-
molecule database, thus allowing the identification of NSC12
as an ARPCA mimic. As anticipated, NSC12 binds FGF2 with a
1:1 stoichiometry and inhibits the formation of bioactive HSPG/
FGF2/FGFR1 ternary complexes by inhibiting FGF2/FGFR
interaction with no effect on FGF2/heparin interaction. Also,
MD simulation-based studies of the FGF2/ARPCA and FGF2/
NSC12 systems indicate that, because of the design process,
both molecules may engage the FGF2 surface that faces the
FGFR D3 domain and D2-D3 linker. Moreover, NSC12 further
extends its interaction into the FGF2 region facing the FGFR
D2 domain. Accordingly, NMR relaxation data showed the ability
of NSC12 to cause the dissociation of the FGF2/D2 complex.
Even though further experiments involving the D2-D3 FGFR
domains will be required to fully elucidate the inhibitory mecha-
nism of NSC12, the combined MD, NMR, biochemical, and
biological data provide compelling evidence of the ability of the
compound to act as an FGF antagonist.
Previous studies had identified the small molecule sm27 as a
mimic of the FGF2-binding sequence of thrombospondin-1
able to engage the heparin-binding site of FGF2 (Pagano et al.,
2012). As observed for other anionic compounds (Presta et al.,
2005), sm27 may interact with the heparin-binding domain of a
variety of signaling proteins with possible unsought side effects.
In contrast, the action of NSC12 appears to be restricted to
FGF family members due to its direct effect on FGF/FGFR inter-
action with no effect on the heparin-binding VEGF-A165 isoform.
Accordingly, NSC12 inhibits the proliferation of various FGF-
dependent murine and human cancer cell lines with no inhibitoryDU145 (E) or H520 (F) cells or FGF-independent human HCC827 (G) cells were
n = 4–6mice/group). Harvested plugs were weighed, and immunofluorescence
TUNEL, and Ki67]). Data are mean ± SEM. In box and whiskers graphs, boxes
d whiskers indicate the range of values. **p < 0.01, #p < 0.001, and xp < 0.05
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Figure 7. Anti-tumor and Anti-metastatic Activity of NSC12
(A) Growth of s.c. TRAMP-C2, DU145, and H520 tumors in mice treated i.p. (arrows) with NSC12, NSC21, or vehicle (n = 10–16 mice/group).
(B) B16-F10-luc cells were injected i.v., and mice were treated i.p. for 2 weeks every other day with NSC12, NSC21, or vehicle (n = 6–8 mice/group). Biolumi-
nescence imaging of lung colonization at day 21 is shown as is count of lung macrometastases at day 28.
(C)Numberof spontaneous lungmacrometastases5weeksafter primaryEO771 tumor removal and treatmentwithDMSO,NSC12,orNSC21 (n=8–10mice/group).
(legend continued on next page)
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effect on HCC827 cancer cells that harbor a tumor-driving muta-
tion of the EGFR TK domain and on FGF-independent cancer cell
lines. Thus, NSC12 may act as a selective ‘‘two-compartment’’
epithelial-stromal targeting agent in FGF/FGFR-dependent
tumors. Accordingly, i.p. and gavage administration of NSC12
hampers FGFR phosphorylation, angiogenesis, and primary
and metastatic growth of FGF-dependent murine and human
tumors in mice.
The FGF/FGFR system is implicated in various steps of tumor
growth and progression (Beenken and Mohammadi, 2009). In
addition, activation of the FGF/FGFR pathway is a mechanism
of tumor escape in response to anti-VEGF therapies (Casanovas
et al., 2005; Lieu et al., 2011). Thus, FGF blockademay represent
a valid therapeutic option for selected tumors driven by an
aberrant ligand-dependent FGFR activation (Dieci et al., 2013).
However, the development of drugs specifically targeting the
FGF/FGFR pathway proved to be difficult, in part due to the
high redundancy and pleiotropic effects of FGF and FGFR family
members. Blockade of FGFR signaling by selective or broad-
spectrum TK inhibitors has been associated with toxicity (Dieci
et al., 2013), and a monoclonal antibody directed against
FGFR1 has failed because of severe weight loss associated
with hypothalamic binding (Sun et al., 2007). On the other
hand, an allosteric multi-FGFR blocker with promising therapeu-
tic implications has been described recently (Bono et al., 2013).
Drugs targeting FGF ligands may represent an interesting
alternative to FGFR inhibitors. They include monoclonal anti-
bodies and FGFR-derived decoy molecules acting as FGF traps
(Harding et al., 2013; Ho et al., 2014). Thesemolecules, however,
have various limitations due to their proteinaceous origin. Our
data demonstrate that NSC12 interacts with all members of
the canonical FGF subfamilies involved in the growth of different
human tumors (Ronca et al., 2015). Moreover, NSC12 prevents
FGF interaction with all four FGFRs. Thus, NSC12 represents a
small-molecule multi-FGF trap with potential implications for
cancer therapy. Of note, in keeping with the lack of pathological
consequences following constitutive hPTX3 expression in
transgenic mice, the anti-tumor action of NSC12 occurred in
the absence of any systemic toxic effect in treated animals.
In particular, in contrast to the hyperphosphatemic effect of
FGFR TK inhibitors in preclinical models (Brown et al., 2005)
and cancer patients (Dieci et al., 2013), long-term administration
of NSC12 did not affect the blood levels of phosphorus, calcium,
and FGF23. Moreover, qRT-PCR analysis did not show any
change of Fgf23 expression in kidneys and bone of NSC12-
treated mice (data not shown). This occurred despite the
capacity of NSC12 to affect the mitogenic activity of hormonal
FGFs, including FGF23, when tested on MDA-MB-361 breast
cancer cells. These observations are in keeping with the safety
profile of the FGFR1-derived FGF trap FP-1039 (Harding et al.,
2013) and of the allosteric multi-FGFR blocker SSR128129E
(Bono et al., 2013). Together, these findings suggest that hyper-(D) Inhibition of FGFR1 activation in s.c. TRAMP-C2/alginate plugs after 4-day o
quantified and normalized to DAPI area. Scale bar, 30 mm.
(E) Growth of H520 tumors in mice orally treated (arrows) with NSC12, NSC21, or v
weighed (n = 10–12 mice/group).
Data are mean ± SEM. In box and whiskers graphs, boxes extend from the 25th to
range of values. *p < 0.05, **p < 0.01, #p < 0.001, and ns = not significant. See aphosphatemia may represent a side effect of FGFR TK inhibitors
rather than of extracellular inhibitors of the FGF/FGFR system.
Given that both FGF23 expression and activity are under the
control of a complex mechanism of regulation that includes ca-
nonical, noncanonical, and intracrine FGF/FGFR pathways (Mar-
tin et al., 2012; Han et al., 2015), further studies are required to
elucidate this point.
Data from phase I and II clinical trials indicate that inhibition of
the FGF/FGFR systemmay show anti-tumor activity and provide
an incentive to develop additional safer and more efficacious
drugs (Dieci et al., 2013). NSC12 represents a lead compound
for the development of orally active small-molecule therapeutics
for the treatment of tumors in which the ligand-dependent
activation of the FGFR pathway is an oncogenic driver or is
involved in the escape to conventional anti-cancer/anti-angio-
genic therapies. Finally, from a broader perspective, our data
emphasize the possibility to exploit protein interactome for the
design of orally active small-molecule multi-ligand traps with
promising implications in cancer therapy.
EXPERIMENTAL PROCEDURES
Reagents and Cell Cultures
Reagents, recombinant proteins, and cell line cultures are detailed in the
Supplemental Experimental Procedures.
NSC12 Identification
Molecular dynamics simulations of ARPCA and NSC12, generation of a
structural ARPCA-FGF2 complex model, pharmacophore model generation,
screening process and parameters, and NMR analysis are detailed in the
Supplemental Experimental Procedures.
Western Blotting and PCR Analyses
Tissues and tumor lysates were separated by SDS-PAGE and immunodeco-
rated with specific antibodies as described in the Supplemental Experimental
Procedures. RT-PCR and qRT-PCR were performed using equal amounts of
input RNA and applying specific amplification conditions as detailed in the
Supplemental Experimental Procedures.
Surface Plasmon Resonance and CONAMORE
SPR analyses were performed using a BIAcore X-100 apparatus (BIAcore).
Experimental conditions for SPR and details for CONAMORE analyses are
described in the Supplemental Experimental Procedures.
Angiogenesis Assays
In vitro endothelial cell sprouting, ex vivo murine aorta ring, and in vivo CAM
and Matrigel plug assays are described in the Supplemental Experimental
Procedures.
Other Assays
Protocols used for cell proliferation, cell-cell adhesion, immunostaining,
and other in vitro assays are detailed in the Supplemental Experimental
Procedures.
Transgenic Mice
TgN(Tie2-hPTX3) mice were generated via injection of vesicular stomatitis
virus G protein (VSV-G)-pseudotyped Tie2-hPTX3 lentiviral particles intoral treatment with NSC12 (7.5 mg/Kg; 4–6 mice/group). pFGFR1/FGFR1 was
ehicle. At the end of the experiment, harvested tumors were photographed and
the 75th percentiles, lines indicate the median values, and whiskers indicate the
lso Figure S6.
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C57BL/6 embryos. Tie2-hPTX3-manipulated embryos were implanted into the
oviduct of pseudopregnant CD1 mice, pups were genotyped for the presence
of hPTX3 and lentiviral vector backbone, and the transgenic strain was main-
tained as described in the Supplemental Experimental Procedures. TRAMP
mice were purchased from the Jackson Laboratory. Double-transgenic
TgN(Tie2-hPTX3)/TRAMP mice were generated by crossing homozygous
TRAMP females with Tie2-hPTX3 males.
Animal Experiments
Subcutaneous tumor models were performed by injecting TRAMP-C2 (5 3
106), LLC (5 3 104), and B16-F10 (1 3 104) cells into the flank of C57BL/6
mice; human H520, DU145, and HCC827 cells were injected (5 3 106) into
the flank of nude mice. Tumor growth was measured by using calipers, and
tumor volume (V) was calculated as follows: V = (length 3 width2) 3 0.5. For
experimental metastasis assays, M5076 (33 104) and B16-F10 (13 104) cells
were injected via the tail vein. Panc02 cells were used for orthotopic tumor
growth, and EO771 cells were used for orthotopic and spontaneous metas-
tasis models. Experimental conditions, tumor and metastasis assays, treat-
ments, and all procedures are detailed in the Supplemental Experimental
Procedures.
Ethical Regulations
Animal experiments were approved by our local animal ethics committee
(OPBA) at the University of Brescia and were executed in accordance with
national guidelines and regulations.
Statistical Analyses
Statistical analyses were performed using the statistical package Prism 5
(GraphPad Software) as detailed in the Supplemental Experimental Proce-
dures. Differences were considered significant with p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccell.2015.07.002.
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